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 Morphofunctional Alterations in Endocrine Pancreas 
of Short- and Long-term Dexamethasone-treated Rats 
from long-term dexamethasone experimental 
models. However, whether these islet compensa-
tions occur before, concomitant with, or after the 
development of dexamethasone-induced IR in 
rodent models is still a matter for debate. 
 Thus, the aim of this study was to characterize 
the development of IR, as well as the functional 
and structural alterations in the pancreatic islets 
during 3 distinct periods of dexamethasone 
treatment; after 1 (short-term), 3, or 5 consecu-
tive days (long-terms) of daily high dose dexam-
ethasone administration. 
 Materials and Methods 
 ▼ 
 Materials 
 Dexamethasone phosphate (Decadron  ®  ) was 
purchased from Ach é (Campinas, SP, Brazil). 
Human recombinant insulin (Biohulin  ®  N) was 
from Biobr á s (Montes Claros, MG, Brazil). The 
 Introduction 
 ▼ 
 Clinical use of glucocorticoids is based on their 
ability to reduce infl ammatory processes and 
immune activation. Despite these desired eff ects, 
glucocorticoid therapies may also result in vari-
ous undesirable eff ects  [1] . Peripheral insulin 
resistance (IR) is one of these adverse eff ects and 
may be observed when dexamethasone is admin-
istered in excess. IR results from a direct gluco-
corticoid impairment of insulin action both in 
hepatic and extrahepatic tissues  [2] . As pancre-
atic islet function is reciprocally related to 
peripheral insulin sensitivity, the amount of cir-
culating insulin is adaptively increased during IR 
 [3] . To account for this enhanced metabolic 
demand of insulin, adaptations in endocrine pan-
creas generally occur including augmentation in 
beta-cell function and proliferation  [4 – 7] . 
 Knowledge concerning these functional and 
structural adaptive compensations has derived 
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 Abstract 
 ▼ 
 Long-term dexamethasone therapy may induce 
peripheral insulin resistance (IR), which in turn 
elicits increased beta-cell function and prolifera-
tion. However, whether such adaptive compen-
sations occur during short-term treatment with 
dexamethasone is unclear. Here, we compared 
morphofunctional parameters in endocrine 
 pancreas after short- and long-term dexametha-
sone administration. Groups of rats received daily 
i.  p. injection of 1  mg / kg b.  w. dexamethasone 
for 1 (DEX-1), 3 (DEX-3), or 5 consecutive days 
(DEX-5), whilst control rats were saline-treated 
(CTL). Despite the absence of apparent IR in 
DEX-1 rats, this group exhibited increased cir-
culating insulin levels and glucose-stimulated 
insulin secretion (GSIS), compared to the CTL 
group (p  <  0.05). Evident IR as well as marked 
hyperinsulinemia and GSIS, as judged by the 
static and dynamic insulin secretion values, were 
observed in DEX-3 and DEX-5 rats (p  <  0.05). 
GSIS in islets cultured with 1  μ M dexamethasone 
was lower compared to the control (p  <  0.05). 
Marked increases in beta-cell proliferation were 
observed in DEX-3 and DEX-5 rats, compared 
to CTL and DEX-1 rats (p  <  0.05). The alterations 
observed in DEX-3 rats were more pronounced 
in DEX-5 rats, which also exhibited a higher con-
tent of islet Cdk4 and Cd2 proteins, compared to 
the CTL group (p  <  0.05). We conclude that short-
term dexamethasone treatment (DEX-1) induces 
an increase in beta-cell function that does not 
require the presence of discernible IR. As the 
treatment continues, the IR develops rapidly, 
and increased insulin secretion as well as beta-
cell hyperplasia is demanded for the appropriate 
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reagents used in the insulin secretion protocols, radioimmu-
noassay (RIA), primary islet culture, histology and immuno-
chemistry were from Mallinckrodt Baker, Inc. (Paris, Kentucky, 
France), Merck (Darmstadt, Germany), and Sigma (St. Louis, MO, 
USA). The  125 I-labeled insulin (human recombinant) for RIA assay 
was purchased from PerkinElmer (Waltham, MA, USA). SDS-
PAGE and immunoblotting was performed using Bio-Rad sys-
tems (Hercules, CA, USA) and all chemicals used were from 
Bio-Rad and from Sigma.  
 Animals and dexamethasone treatment 
 Experiments were performed on groups of male Wistar rats 
(3-months old). The rats were obtained from the University of 
Campinas Animal Breeding Center and were kept at 24   °  C on a 
12-h light / dark cycle. Rats had access to food and water ad libi-
tum. Experiments with animals were approved by the institu-
tional S ã o Paulo State University Committee for Ethics in Animal 
Experimentation and conform to the Guide for the Care and Use 
of Laboratory Animals published by the US National Institutes of 
Health (NIH publication No. 85-23 revised 1996). Rats were dis-
tributed as follows: rats that received daily i.  p. injection of 1  mg /
 kg b.  w. dexamethasone for 1 (DEX-1) (short-term), 3 (DEX-3) or 
5 (DEX-5) consecutive days (long-terms), whereas the control 
(CTL) group received saline (NaCl 0.9  % ) for 5 consecutive days, 
between 7:30 – 8:30  h. Daily injection were adjusted in a manner 
that all groups of rats: CTL, DEX-1, DEX-3, and DEX-5 were sacri-
fi ced on the same day (the day after the last saline or dexame-
thasone administration). 
 Metabolic and hormonal measurements and peripheral 
sensitivity tests 
 Blood was collected from the tail tip of fasted (12 – 14  h) or fed 
rats and blood glucose levels were measured with a glucometer 
( “ one touch ”  – Johnson  & Johnson). Immediately afterwards, 
animals were sacrifi ced (exposure to CO 2 followed by decapita-
tion) and the trunk blood was collected. The serum, obtained by 
centrifugation, was used to measure fasted or fed insulin, trig-
lycerides, and total protein, and albumin levels according to 
Rafacho et  al.  [8] . Determination of hepatic glycogen was per-
formed, as previously described  [9] . Intraperitoneal insulin 
(ipITT) and glucose tolerance test (ipGTT) were performed in 
separate groups of rats, according to a detailed previous descrip-
tion  [8] . 
 Islet isolation, primary islet culture, islet insulin 
content, and static and dynamic secretion protocols 
 Islets were isolated by collagenase digestion of the pancreas. For 
primary islet culture, islets were isolated from normal adult 
Wistar rats and cultured for 18  h in RPMI-1640 medium supple-
mented with 100  IU of penicillin / ml, 100  μ g of streptomycin / ml 
and 250  ng / ml amphotericin at 37   °  C in a 5  % CO 2 / air atmosphere 
under the following  conditions: 1) 11.1  mM glucose  +  10  % fetal 
bovine serum (FBS)  without or 2) with 1.0  μ M dexamethasone 
and 3) 5.6  mM glucose  +  0  % FBS without or 4) with 200  pM insu-
lin (a concentration known to induce primary beta-cell prolifer-
ation in culture  [10] ). Islets from primary culture were used for 
static insulin secretion protocols, whilst freshly isolated islets 
from CTL and all dexamethasone-treated groups were used for 
determination of islet insulin content and insulin secretion 
 protocols (static and dynamic), as described previously in detail 
 [8] .  
 Quantitative approaches in endocrine pancreas 
 To study the morphometric parameters of endocrine pancreas, 5 
pancreases from each group were excised and processed accord-
ing to a previous description  [11] .  
 Beta-cell proliferation and death 
 The beta-cell proliferation was estimated by the percentage of 
PCNA-positive cells from the total of insulin-positive cells, as 
described previously in detail  [11] . Detection of DNA fragmenta-
tion in situ was visualized with the use of the ApopTag Plus 
 Peroxidase In Situ Apoptosis Detection Kit (Chemicon Interna-
tional, Norcross, GA, USA). The beta-cell death was estimated by 
the percentage of TUNEL-positive cells from the total of insulin-
 positive cells, as described previously in detail  [6] .  
 Protein extraction and immunoblotting 
 Protein extraction and immunoblotting were carried out as pre-
viously reported in detail  [6,  11] . 
 Statistical analysis 
 Results are expressed as the means  ±  SEM of the indicated 
number (n) of experiments. Analysis of variance (one way  – 
ANOVA), for unpaired groups, followed by Tukey post test was 
utilized for multiple comparisons of parametric data. The sig-
nifi cance level adopted was p  <  0.05.  
 Results 
 ▼ 
 Characteristics of the rats 
 On the day of experiments, decreased body weight was observed 
in DEX-3 and DEX-5, compared to CTL and DEX-1 rats (  ● ▶  Table  1 ; 
n  =  10; p  <  0. 05). The adrenal mass (bilateral glands) was reduced 
in all dexamethasone-treated groups (  ● ▶  Table  1 ; n  =  10 glands 
from 5 rats; p  <  0.01). The fasting hepatic glycogen content 
 values were 2.2- and 2.0-fold higher in DEX-3 and DEX-5, com-
pared to CTL rats (  ● ▶  Table  1 ; n  =  10; p  <  0.01). Blood glucose and 
serum parameters at fasting and fed conditions are shown 
in   ● ▶  Table  1 . Glycemic values were similar among the 4 groups 
at fasting state. Fed blood glucose tended to be higher in DEX-5 
vs. CTL rats, but it was not signifi cant (n  =  10). The serum insulin 
values increased in a time-dependent manner in both nutri-
tional states, being higher in all dexamethasone-treated groups 
than in CTL ones (  ● ▶  Table  2 ; n  =  10, p  <  0.05). The levels of serum 
triglyceride were signifi cantly enhanced in DEX-3 and DEX-5 
rats under  fasting condition, but only in DEX-5 rats in fed condi-
tion,  compared to CTL group (n  =  10, p  <  0.05). Total serum pro-
tein and albumin concentrations were higher in DEX-3 and 
DEX-5 vs. CTL rats under fasting and fed conditions (  ● ▶  Table  2 ; 
n  =  10, p  <  0.01). 
 Table 1  Body weight, adrenal mass, and hepatic glycogen in control (CTL) 
and 1-(DEX-1), 3-(DEX-3), and 5-day dexamethasone-treated rats (DEX-5) 
  Body 
weight (g) 
 Adrenal mass 
(mg / 100  g b.w.) 
 Hepatic glycogen 
(mg / 100  mg b.w.) 
 CTL  362  ±  6  18.6  ±  0.5  2.1  ±  0.3 
 DEX-1  357  ±  10  15.6  ±  0.6 a  2.7  ±  0.3 
 DEX-3  323  ±  9 a,b  13.2  ±  0.7 a,b  4.5  ±  0.2 a,b 
 DEX-5  314  ±  8 a,b  12.7  ±  0.5 a,b  4.1  ±  0.3 a,b 
 Values are means  ±  SEM; n  =  10 
 a  Signifi cantly diff erent vs. CTL and  b  vs. DEX-1 
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 Insulin sensitivity and glucose tolerance 
 The constant rate for glucose disappearance values ( K itt), 
obtained through ipITT experiments, indicated a tendency 
towards a reduction in insulin sensitivity in DEX-1 (not signifi -
cant) and a marked IR in DEX-3 and DEX-5, compared to CTL rats 
(  ● ▶  Fig.  1a ; p  <  0.001). The  K itt values were 3.8  ±  0.4, 2.9  ±  0.4, 
1.7  ±  0.2, and 1.6  ±  0.2  %  ·  min  – 1 for CTL, DEX-1, DEX-3, and DEX-5 
rats, respectively (n  =  7). DEX-5 rats showed decreased glucose 
tolerance after 2  g / kg glucose load, compared to CTL rats 
(  ● ▶  Fig.  1b ; n  =  7, p  <  0.05). The area-under-glucose-curve (AUC) 
values were 218.8  ±  35.0, 201.8  ±  16.1, 259.7  ±  14.7, and 
341.1  ±  41.9  mg / dl  ·  min  – 1 for CTL, DEX-1, DEX-3, and DEX-5 rats, 
respectively. After 10  min of glucose administration, the insulin 
response was increased in all rat groups (  ● ▶  Fig.  1c ; compare 
with fasting serum insulin values in   ● ▶  Table  1 ). This insulin 
response to intraperitoneal glucose load was signifi cantly higher 
in DEX-5, compared to CTL rats (n  =  5, p  <  0.05). The insulin 
response tended to be higher also in DEX-1 and DEX-3, com-
pared to CTL group, but it was not statistically signifi cant. 
 Insulin secretion from isolated islets 
 Experiments with static incubation revealed an augmented 
insulin secretion in response to increasing glucose concentra-
tions in islets from all dexamethasone-treated rats, except for 
2.8  mM glucose in DEX-1, compared to CTL islets (  ● ▶  Fig.  2a ; 
n  =  15 wells, p  <  0.01).   ● ▶  Fig.  2 shows the dynamic insulin release 
in perifused islets from CTL and dexamethasone-treated rats 
under 2.8 and 11.1  mM glucose. As expected, the biphasic insu-
lin secretion was observed in CTL islets (  ● ▶  Fig.  2b ). Insulin 
secretion in islets from DEX-1, DEX-3, and DEX-5 rats also exhib-
ited a biphasic pattern with higher insulin values than CTL islets 
(  ● ▶  Fig.  2c – e ). The area-under-curve (AUC) between the fi rst 
10  min after the introduction of 11.1  mM glucose revealed a sig-
nifi cant increase in insulin response in islets from all dexameth-
asone-treated rats, compared to the CTL response (n  =  4, p  <  0.05). 
The AUC values were 631  ±  198, 8  740  ±  2  081, 12  662  ±  2  007 and 
12  638  ±  2  474  pg / 20 islets  ·  ml   −  1  ·  min   −  1 for CTL, DEX-1, DEX-3, 
and DEX-5 rats, respectively. The AUC values obtained during 
the second phase (from 30 to 56  min) were higher in all DEX islet 
groups, compared to CTL group (n  =  4, p  <  0.05; only for DEX-3 
group). The insulin secretion returned to basal values with the 
re-introduction of 2.8  mM glucose in all islet groups. 
  CTL  DEX-1  DEX-3  DEX-5 
 Fasting 
 Glucose (mg / dl)  90.6  ±  2.3  100.7  ±  2.3  98.5  ±  4.3  99.2  ±  3.6 
 Insulin (ng / ml)  2.4  ±  0.3  6.4  ±  0.5 a  9.3  ±  1.3 a  14.3  ±  2.1 a,b 
 TG (mg / dl)  106.6  ±  14.7  126.0   ±  15.2  216.4  ±  24.3 a  343.6  ±  38.1 a,b,c 
 T-protein (g / dl)  7.1  ±  0.1  7.8  ±  0.2 a  8.1  ±  0.1 a  7.9  ±  0.1 a 
 Albumin (g / dl)  3.2  ±  0.1  3.2  ±  0.1  4.3  ±  0.1 a,b  4.6  ±  0.1 a,b 
 Fed 
 Glucose (mg / dl)  109.0  ±  2.0  109.2  ±  3.9  114.2  ±  4.7  137.2  ±  20.7 
 Insulin (ng / ml)  2.6  ±  0.4  5.9  ±  0.7 a  11.5  ±  1.5 a  15.7  ±  2.6 a,b 
 TG (mg / dl)  189.0  ±  14.2  147.4   ±  18.6  187.9  ±  26.5  289.2  ±  26.2 a,b,c 
 T-protein (g / dl)  6.1  ±  0.2  6.7  ±  0.1  7.0  ±  0.1 a  7.2  ±  0.1 a 
 Albumin (g / dl)  2.6  ±  0.1  3.1  ±  0.1 a  3.5  ±  0.1 a,b  3.8  ±  0.1 a,b 
 Values are means  ±  SEM; n  =  10 
 a  Signifi cantly diff erent vs. CTL,  b  vs. DEX-1, and  c  vs. DEX-3 
 p  <  0.05 for 1-way ANOVA using Tukey’s post test 
 TG: triglycerides; T-protein: total protein 
 Table 2  Blood glucose and serum 
parameters in control (CTL) and 
1-(DEX-1), 3-(DEX-3), and 5-day 
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 Fig. 1  Peripheral insulin and glucose sensiti-
vity.  a : The intraperitoneal insulin tolerance test 
in control (CTL), and 1-(DEX-1), 3-(DEX-3) and 
5-day dexamethasone-treated rats. Note the 
decreased constant rate for glucose disappearance 
values ( K itt) in DEX-3 and DEX-5 rats. Data are 
means  ±  SEM; n  =  7.  a  Signifi cantly diff erent vs. CTL 
and  b  signifi cantly diff erent vs. DEX-1. p  <  0.05 for 
1-way ANOVA using Tukey ’ s post test.  b : The intra-
peritoneal glucose tolerance test in control (CTL), 
and 1-(DEX-1), 3-(DEX-3) and 5-day dexametha-
sone-treated rats. Note the augmented area-under-
glucose-curve (AUC) values in DEX-5 rats. Data are 
means  ±  SEM; n  =  7.  a  Signifi cantly diff erent vs. CTL 
and  b  signifi cantly diff erent vs. DEX-1. p  <  0.05 for 
1-way ANOVA using Tukey ’ s post test.  c : Insulin 
secretion in vivo after 10  min glucose load during 
ipGTT experiments. Data are means  ±  SEM; n  =  5. 
 a  Signifi cantly diff erent vs. CTL. p  <  0.05 for 1-way 
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 Insulin secretion in primary islet culture 
 Isolated islets cultured for 18  h in the absence or presence of 
1  μ M dexamethasone was performed to test whether the direct 
eff ects of the glucocorticoid corroborates with the increased 
insulin response observed in vivo in DEX rats. As expected, glu-
cose at stimulatory concentrations (11.1 or 22  mM) augmented 
insulin release in islets cultured in absence of dexamethasone, 
when compared to basal conditions (2.8 and 5.6  mM glucose) 
(  ● ▶  Fig.  3a ; n  =  8 wells, p  <  0.05). Islets cultured in presence of 
1  μ M dexamethasone did not exhibit such increase in insulin 
release under glucose stimuli (11.1 or 22  mM), compared to low 
glucose concentrations (2.8 and 5.6  mM) (n  =  8 wells), being sig-
nifi cantly reduced in relation to control values (  ● ▶  Fig.  3a ; 
p  <  0.05). In another set of insulin secretion experiments, GSIS 
was performed in primary cultured islets (18  h) in the presence 
of 200  pM insulin to test whether this component could result in 
alteration of insulin response to glucose. According to   ● ▶  Fig.  3b , 
islets cultured in 200  pM insulin medium had similar insulin 
response when stimulated with 11.1 or 22  mM glucose, com-
pared to control islets (cultured with 5.6  mM glucose  +  0  % FBS) 
(n  =  8 wells). The increase in GSIS was similar in both groups 
(p  <  0.05). 
 Beta-cell proliferation and death 
 5-day dexamethasone administration induces increased pancre-
atic rat beta-cell proliferation  [6,  11] . Herein, we confi rmed the 
marked beta-cell proliferation, as judged by the large distribu-
tion of PCNA-positive nuclei in DEX-5, compared to CTL islets 
(  ● ▶  Fig.  4a, b ; n  =  40 – 50 islets, p  <  0.001). DEX-3 rats also showed 
a higher frequency of beta-cell proliferation, compared to CTL 
(p  <  0.05); however, this parameter was similar between DEX-1 
and CTL rats (  ● ▶  Fig.  4a, b ). TUNEL analysis in pancreas sections 
did not reveal diff erences in beta-cell apoptosis between the 4 
groups. The percentage of TUNEL insulin-positive cells were 
0.16  ±  0.04, 0.14  ±  0.05, 0.13  ±  0.05, and 0.17  ±  0.06 for CTL, DEX-1, 
DEX-3, and DEX-5, respectively (n  =  40 – 50 islets). 
 Cell-cycle protein levels 
 Irs-2 (rather than Irs-1), Akt, Cd1 / 2, and Cdk4 proteins are all 
associated with the control of beta-cell proliferation. Levels of 
Irs-1 and Irs-2 protein were similar among the 4 groups, although 
a tendency towards an increase in DEX-3 and DEX-5, compared 
to CTL islets was observed for both components (  ● ▶  Fig.  4c ; n  =  6). 
Akt and Cd1 protein contents were also similar in islets of all 
groups. With regard to Cd2 protein, increases of 41  % and 63  % 
were observed in DEX-3 and DEX-5, respectively, vs. CTL islets 
(  ● ▶  Fig.  4c ; n  =  6, p  <  0.05 for DEX-5 only). Finally, levels of Cdk-4 
protein were found to be higher (120  % ) in DEX-5 islets (n  =  6, 
p  <  0.01), and tended to be higher in DEX-1 and DEX-3, when 
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0 time (min)8070605040302010 0 time (min)8070605040302010
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 Fig. 2  Glucose-stimulated insulin secretion in 
freshly isolated islets.  a : Cumulative static insulin 
secretion in islets isolated from control (CTL), 
and 1-(DEX-1), 3-(DEX-3) and 5-day dexametha-
sone-treated rats (DEX-5). Note the higher insulin 
 response to crescent glucose stimuli in isolated 
islets from all dexamethasone-treated rats, in 
relation to CTL responses. Values are means  ±  SEM; 
n  =  15 wells in 2 diff erent experiments.  a  Signif-
icantly diff erent vs. CTL,  b  vs. DEX-1 and  c  vs. 
DEX-3. p  <  0.05 for 1-way ANOVA using Tukey ’ s 
post test.  b – e : Dynamic insulin secretion in islets 
isolated from CTL, DEX-1, DEX-3, and DEX-5 rats. 
Observe the biphasic insulin response in CTL 
( b ) and the pronounced insulin response under 
11.1  mM glucose stimulation in DEX-1 ( c ), DEX-3 
( d ), and DEX-5 ( e ) islets. Values are means  ±  SEM; 
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 Discussion and Conclusions 
 ▼ 
 Long-term dexamethasone administration, at high doses, 
induces IR that is generally accompanied by several endocrine 
pancreas adaptive compensations. Among them, beta-cell hyper-
secretion  [4,  7,  8,  12] and beta-cell hyperplasia  [6,  11] guarantee 
the appropriate circulating insulin levels that keep the blood 
glucose at normal or near-normal physiological ranges. Whether 
these alterations may occur before, concomitant with or after 
the apparent development of IR is still a matter for debate. Thus, 
we investigated the eff ects of short-term (DEX-1), and long-term 
(DEX-3 and DEX-5) dexamethasone treatment on morphofunc-
tional aspects of the endocrine pancreas in rats. 
 Dexamethasone-treated rat models are characterized by a reduc-
tion in body weight  [8,  13] , and increases in hepatic glycogen 
content  [9,  14] and serum triglycerides  [13] using a drug admin-
istration (1  mg / kg b.  w.) varying from 5 to 11 consecutive days. 
Similar observations were found for our DEX-3 and DEX-5 rats, 
revealing that these characteristics are well reproducible and 
were present in DEX-5 rats from the third day of dexamethasone 
administration (DEX-3 rats). These metabolic disturbances were 
not observed in DEX-1 rats, suggesting that a single dose was not 
enough to induce them, even with a high dose of 1  mg / kg b.  w . 
 With the exception of a marginal increase in fed blood glucose in 
DEX-5 rats, all groups exhibited normal glycemic range values, 
both in fasting and fed conditions. Dexamethasone-treated rats, 
including DEX-1 rats, showed higher serum insulin levels than 
those of the CTL group (  ● ▶  Table  2 ). The marked hyperinsuline-
mia found in DEX-3 and DEX-5 rats is a well known compensa-
tory adaptation that occurs in response to the striking IR 
observed in these groups. This compensatory response is dem-
onstrated by previous studies in human and rats showing that 
this adaptation occurs from the second day of dexamethasone 
administration and continues thereafter, when the IR imposed 
by the glucocorticoid treatment is apparent  [4,  5,  7,  15 – 17] . DEX-
1 rats do not demonstrate a discernible IR (  ● ▶  Fig.  1a ), and the 
increase in serum insulin levels in this group cannot be attrib-
uted to a compensatory islet insulin response to peripheral insu-
lin resistance. Although we did not detect such a response in our 
ipITT experiments, a previous study using the euglycemic-
hyperinsulinemic clamp showed that a single dexamethasone 
dose (1  mg / kg b.  w.) can induce a signifi cant decrease in periph-
eral insulin sensitivity after 4  h of drug treatment  [18] . Thus, a 
minimal eff ect of reduced insulin sensitivity in these animals 
may be present. However, Qi et  al.  [18] did not observe any 
increase in circulating insulin levels after 4  h. A possible expla-
nation for the increased circulating insulin levels in DEX-1 rats 
may come from a central component. When administered 
directly to the central nervous system, dexamethasone increases 
the activity of the parasympathetic system resulting in aug-
mented circulating insulin levels  [19] . As previously shown, 
vagotomized rats treated with dexamethasone for 5 consecutive 
days at 1  mg / kg b.  w., showed a lower level of hyperinsulinemia, 
but the same degree of insulin resistance, compared with con-
trol rats (without vagotomy) suggesting the participation of the 
cholinergic system in pancreatic islets during glucocorticoid 
treatment  [20] . In an elegant study, Ahr é n  [21] demonstrated 
that the higher insulin response to arginine in insulin-resistant 
state, induced by dexamethasone treatment in healthy women, 
was reduced when dexamethasone treatment was conjugated 
with trimethaphan, a ganglia neurotransmission blocker. Thus, 
it is possible that our DEX-1 rats exhibit an early parasympa-
thetic activation that results in such response. Given that DEX-1 
rats have normal blood glucose and serum lipid concentrations, 
we cannot attribute a role for such circulating components on 
the process of insulin secretion in vivo during the period of 
24  h . 
 Long-term dexamethasone treatment of adult rats with doses 
varying between 0.125 and 2.0  mg / kg effi  ciently augment the 
islet insulin response to several secretagogues, especially to glu-
cose  [4,  7,  8,  12,  16] . Increased GSIS in these animal models is 
mediated by augmented glucose responsiveness  [4,  8,  16] , mito-
chondrial function  [7,  16] , and intracellular calcium handling 
 [7] . The protein kinases A and C  [16,  22] and cholinergic pathway 
are also involved in this increased islet function under the 
a




























































 Fig. 3  Glucose-stimulated insulin secretion in primary islet culture. 
 a : Cumulative static insulin secretion in islets cultured without or with 
1  μ M dexamethasone for 18  h. Observe the reduced insulin secretion in 
response to glucose stimuli in dexamethasone-cultured islets. Values 
are means  ±  SEM; n  =  8 wells in 2 diff erent experiments.  a  Signifi cantly 
diff erent vs. 2.8  mM and  b  vs. 5.6  mM glucose, and  #  Signifi cantly diff erent 
vs. control group (without dexamethasone). p  <  0.05 for 1-way ANOVA 
using Tukey ’ s post test.  b : Cumulative static insulin secretion in islets 
cultured without or with 200  pM insulin for 18  h. Note similar glucose-
stimulated insulin secretion in both islet groups. Values are means  ±  SEM; 
n  =  8 wells in 2 diff erent experiments.  a  Signifi cantly diff erent vs. 2.8  mM, 
 b  vs. 5.6  mM and  c  vs. 11.1  mM glucose. p  <  0.05 for 1-way ANOVA using 
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 glucocorticoid-induced IR  [20] . Interestingly, GSIS from DEX-1 
islets is signifi cantly augmented when challenged by diff erent 
glucose stimuli (  ● ▶  Fig.  2a, c ). Such insulin response may not be 
attributed to a direct eff ect of dexamethasone since primary 
cultured islets, in the presence of 1  μ M dexamethasone, had 
decreased insulin response to stimulatory glucose concentra-
tions (  ● ▶  Fig.  3a ). Furthermore, the role of elevated circulating 
insulin on the islet response to glucose seems to be not signifi -
cant, at least for a short period, as judged by the similar GSIS in 
islets cultured with 200  pM insulin, compared to those cultured 
without insulin (  ● ▶  Fig.  3b ). Thus, additional studies merit inves-
tigation to explore the mechanisms underscoring beta-cell adap-
tation upon such a condition. 
 Conditions in which the demand by insulin is normally increased, 
such as obesity  [23] and exogenous glucocorticoid administra-
tion  [6,  8] , require an elevation in circulating insulin levels that is 
achieved by increased beta-cell function. Depending on the 
magnitude of the IR, augmentation in beta-cell mass participates 
in the compensatory adaptations. Increases in beta-cell mass, 
induced by long-term dexamethasone treatment, results from 
both beta-cell hyperplasia  [6,  11] and hypertrophy  [6] . Beta-cell 
proliferation was markedly increased in DEX-5 rats (  ● ▶  Fig.  4a, b ) 
and is associated with an augmented cyclin d2 (Cd2) and cyclin-
dependent kinase 4 (Cdk4) protein content in islets (  ● ▶  Fig.  4c ). 
Of note, we showed a 4.4-fold increase in beta-cell proliferation 
in DEX-3 rats, suggesting a high requirement for insulin from the 
third day of dexamethasone treatment to enable maintenance of 
glucose homeostasis. Since DEX-1 rats do not exhibit any altera-
tion in beta-cell growth (proliferation and death), we excluded 
the possibility that dexamethasone exerts a possible direct eff ect 
on beta-cell proliferation in vivo. Rather, this seems to be a proc-
ess that strictly depends on a permanent IR, suggesting a cou-
pling between the peripheral tissues needed for insulin and 
pancreatic beta-cell function. It is important to emphasize that 
most morphofunctional alterations induced by the dexametha-
sone treatment in rats are reversible with the interruption of the 
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 Fig. 4  Beta-cell proliferation and key cell- cycle 
protein levels.  a : Representative images of 
pancreas sections stained for PCNA and insulin 
showing increased numbers of positive nuclei for 
PCNA (arrows) in beta cells from DEX-3 and DEX-5 
rats, whilst this was rarely found in CTL and DEX-1 
islets.  b : Percentage of PCNA positive cell in beta-
cells. Values are means  ±  SEM. n ≅ 3  500 beta-cell 
nuclei.  a  Signifi cantly diff erent vs. CTL,  b  vs. DEX-1 
and  c  vs. DEX-3. p  <  0.001 for 1-way ANOVA using 
Tukey ’ s posttest. Scale bars  =  100  μ m.  c : Western 
blot experiments with islet lysates from control 
(CTL), and 1-(DEX-1), 3-(DEX-3) and 5-day dexam-
ethasone-treated rats (DEX-5). DEX-5 rats showed 
signifi cant increases in Cd2 and Cdk4 protein 
contents, compared to CTL ones. Below the panel, 
a representative control blot for alpha-tubulin is 
shown. Values are means  ±  SEM. The fi gures are 
representative of immunoblots performed at least 
fi ve times on separate islet extracts.  a  Signifi cantly 
diff erent vs. CTL p  <  0.05 for 1-way ANOVA using 
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 Therefore, we conclude that short-term dexamethasone treat-
ment (a period of 24-h duration) induces an increase in beta-cell 
function, which does not require the presence of discernible IR. 
As the treatment continues, IR develops, and increased insulin 
secretion and beta-cell hyperplasia are observed in a time-
dependent manner that accounts for the appropriate mainte-
nance of glucose homeostasis. 
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